Pioneering Advances and Innovative Applications of Mesoporous Carriers for Mitochondria-Targeted Therapeutics DOI Creative Commons

Mohamad Anas Al Tahan,

Sana Al Tahan

British Journal of Biomedical Science, Journal Year: 2024, Volume and Issue: 81

Published: Nov. 18, 2024

Mitochondria, known as the cell’s powerhouse, play a critical role in energy production, cellular maintenance, and stemness regulation non-cancerous cells. Despite their importance, using drug delivery systems to target mitochondria presents significant challenges due several barriers, including uptake limitations, enzymatic degradation, mitochondrial membranes themselves. Additionally, barriers organs be targetted, along with extracellular formed by physiological processes such reticuloendothelial system, contribute rapid elimination of nanoparticles designed for mitochondrial-based delivery. Overcoming these has led development various strategies, molecular targeting cell-penetrating peptides, genomic editing, nanoparticle-based systems, porous carriers, liposomes, micelles, Mito-Porters. Porous carriers stand out particularly promising candidates large pore size, surface area, ease functionalisation. Depending on they can classified micro-, meso-, or macroporous are either ordered non-ordered based both size uniformity. Several methods employed modifications polyethylene glycol (PEG), incorporation ligands like triphenylphosphonium, capping pores gold chitosan enable controlled triggered Photodynamic therapy is another approach, where drug-loaded generate reactive oxygen species (ROS) enhance targeting. Further advancements have been made form functionalised silica carbon nanoparticles, which demonstrated potential effective mitochondria. This review highlights approaches that utilise specifically focusing silica-based efficient vehicles mitochondria, paving way improved strategies therapies.

Language: Английский

Extracellular Vesicle-based Delivery of Paclitaxel to Lung Cancer Cells: Uptake, Anticancer Effects, Autophagy and Mitophagy Pathways DOI

Shabnam Pirnezhad Talatapeh,

Jafar Rezaie, Vahid Nejati

et al.

Archives of Medical Research, Journal Year: 2025, Volume and Issue: 56(4), P. 103194 - 103194

Published: Feb. 7, 2025

Language: Английский

Citations

0
Advances in Cardiac Fibrosis Research and Treatment Development DOI Creative Commons
Yong Sook Kim, Youngkeun Ahn

Journal of Cardiovascular Intervention, Journal Year: 2025, Volume and Issue: 4

Published: Jan. 1, 2025

Language: Английский

Citations

0
Mitochondrial dysfunction in AMI: mechanisms and therapeutic perspectives DOI Creative Commons

Jingle Shi,

Yiding Yu, Huajing Yuan

et al.

Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 10, 2025

Acute myocardial infarction (AMI) and the ischemia-reperfusion injury (MI/RI) that typically ensues represent a significant global health burden, accounting for considerable number of deaths disabilities. In context AMI, percutaneous coronary intervention (PCI) is preferred treatment option reducing acute ischemic damage to heart. Despite modernity PCI therapy, pathological cardiomyocytes due MI/RI remains an important target affects long-term prognosis patients. recent years, mitochondrial dysfunction during AMI has been increasingly recognized as critical factor in cardiomyocyte death. Damaged mitochondria play active role formation inflammatory environment by triggering key signaling pathways, including those mediated cyclic GMP-AMP synthase, NOD-like receptors Toll-like receptors. This review emphasizes dual both contributors regulators inflammation. The aim explore complex mechanisms its profound impact on immune dysregulation. Specific interventions mitochondrial-targeted antioxidants, membrane-stabilizing peptides, transplantation therapies have demonstrated efficacy preclinical models.

Language: Английский

Citations

0
Pioneering Advances and Innovative Applications of Mesoporous Carriers for Mitochondria-Targeted Therapeutics DOI Creative Commons

Mohamad Anas Al Tahan,

Sana Al Tahan

British Journal of Biomedical Science, Journal Year: 2024, Volume and Issue: 81

Published: Nov. 18, 2024

Mitochondria, known as the cell’s powerhouse, play a critical role in energy production, cellular maintenance, and stemness regulation non-cancerous cells. Despite their importance, using drug delivery systems to target mitochondria presents significant challenges due several barriers, including uptake limitations, enzymatic degradation, mitochondrial membranes themselves. Additionally, barriers organs be targetted, along with extracellular formed by physiological processes such reticuloendothelial system, contribute rapid elimination of nanoparticles designed for mitochondrial-based delivery. Overcoming these has led development various strategies, molecular targeting cell-penetrating peptides, genomic editing, nanoparticle-based systems, porous carriers, liposomes, micelles, Mito-Porters. Porous carriers stand out particularly promising candidates large pore size, surface area, ease functionalisation. Depending on they can classified micro-, meso-, or macroporous are either ordered non-ordered based both size uniformity. Several methods employed modifications polyethylene glycol (PEG), incorporation ligands like triphenylphosphonium, capping pores gold chitosan enable controlled triggered Photodynamic therapy is another approach, where drug-loaded generate reactive oxygen species (ROS) enhance targeting. Further advancements have been made form functionalised silica carbon nanoparticles, which demonstrated potential effective mitochondria. This review highlights approaches that utilise specifically focusing silica-based efficient vehicles mitochondria, paving way improved strategies therapies.

Language: Английский

Citations

2